The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Delaying CLL treatment is advised to avoid early recurrence without measurable benefits, with treatment likely needed by 2025. Fatigue from treatment is a major concern, impacting cherished activities ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of cases, patients with CLL will develop lymphoma, a complication known as ...

-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys-CLL is one ...

Blood cancer treatment is entering a new era, bringing powerful breakthroughs that offer renewed hope to people living with leukemia, lymphoma, myeloma, and other blood cancers. Cutting-edge targeted ...

Leukemia and lymphoma are cancers that affect white blood cells, but they are separate conditions. In some people, they can occur simultaneously. It is possible, but very rare, to have both leukemia ...